Pang T, et al. - An open-label study was conducted to provide real-world evidence from the UK about the use of insulin glargine 300 units/ml (U300) in individuals with type 1 diabetes mellitus. For this investigation, researchers included people with type 1 diabetes who were prescribed U300 ≥6 months prior to data collection and had HbA1c levels recorded within 3 months prior to U300 (baseline). Findings suggested an association of a change in basal insulin to U300 with clinically and statistically significant HbA1c improvements, without significant changes in basal insulin dose and weight in people with type 1 diabetes. Before and after U300 initiation, documented severe hypoglycemia episodes and ketoacidosis requiring emergency department visits or hospitalization were low and comparable.